Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02232516 · OUTCOME

Progression-free Survival (PFS)

Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma · Source last updated 2026-06-12

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
PFS Probability
Interval / dispersion
95% Confidence Interval
Time frame
Reported at 1 and 3 years after the start of treatment

What was measured

l be progression-free survival (PFS) 1 and 3 years after start of treatment as well as the duration of response from start of therapy, defined per Cheson criteria.

Groups in this outcome

Treatment (Romidepsin, Lenalidomide)

Patients receive romidepsin IV over 4 hours on days 1, 8, and 15 and lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity. romidepsin: Given IV lenalidomide: Given PO laboratory biomarker analysis: Correlative studies

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Romidepsin, Lenalidomide)23

Reported measurements

PFS at year 1
Values in PFS Probability · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Treatment (Romidepsin, Lenalidomide)0.486Not reported0.3110.759Not reported
PFS at year 3
Values in PFS Probability · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Treatment (Romidepsin, Lenalidomide)0.315Not reported0.1080.615Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0.311
        upper Limit
        0.759
        value
        0.486
    title
    PFS at year 1
  2. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0.108
        upper Limit
        0.615
        value
        0.315
    title
    PFS at year 3
denoms
  1. counts
    1. group Id
      OG000
      value
      23
    units
    Participants
description
l be progression-free survival (PFS) 1 and 3 years after start of treatment as well as the duration of response from start of therapy, defined per Cheson criteria.
dispersion Type
95% Confidence Interval
groups
  1. description
    Patients receive romidepsin IV over 4 hours on days 1, 8, and 15 and lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity. romidepsin: Given IV lenalidomide: Given PO laboratory biomarker analysis: Correlative studies
    id
    OG000
    title
    Treatment (Romidepsin, Lenalidomide)
param Type
NUMBER
reporting Status
POSTED
time Frame
Reported at 1 and 3 years after the start of treatment
title
Progression-free Survival (PFS)
type
SECONDARY
unit Of Measure
PFS Probability

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice